Drugs / AVANZ olea
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01674595 | Sep 2012 → Apr 2013 | allergic rhinitis | ALK-Abelló A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVANZ olea | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01674595 ↗ |
| Route | Subcutaneous | “A new subcutaneous specific immunotherapy (SCIT) product” PMID 26213608 ↗ Jul 2015 |